What is the efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak) for the treatment of hepatitis C (Hep C) infection?

Updated: Oct 07, 2019
  • Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD  more...
  • Print

Ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak)

On December 19, 2014, the FDA approved the combination of ombitasvir/paritaprevir/ritonavir and dasabuvir (Viekira Pak) for the treatment of genotype 1 chronic hepatitis C infection in adults, including patients with compensated cirrhosis. Studies were conducted using two tablets of ombitasvir/paritaprevir/ritonavir tablet once daily (in the morning) plus one tablet of dasabuvir 250 mg tablet twice daily (morning and evening) with a meal with ribavirin (up to six pills divided into two daily doses) for 12 weeks (no cirrhosis) or 24 weeks (compensated cirrhosis) with the cure rates summarized below. [121, 122, 123, 124, 125]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!